A Democratic bill with 24 Democratic cosponsors · See all 24 cosponsors
Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The Drug Deal Disclosure Act requires the Department of Health and Human Services to release documents and communications regarding private drug pricing deals. This includes agreements between federal entities and drug manufacturers entered into on or after January 20, 2025. The bill specifically targets agreements involving reduced prices, direct-to-consumer sales, or exemptions from duties. It covers a specific list of publicly announced agreements with various pharmaceutical companies. The Act mandates that information be made available in a centralized, searchable, and downloadable format. Finally, it requires economic and budgetary analyses of these agreements by the CBO and GAO.
Yes· 3 of 11
- Scored +8
Does this make what the government does easier for the public to see?
The bill requires the public release of documents, communications, and contracts related to drug pricing deals in a searchable format.
- Scored +5
Does this lower the price of prescription medicines?
The bill targets the disclosure of agreements that involve reduced drug prices to increase transparency regarding costs.
- Scored +3
Would households on low incomes be better off under this?
The bill tracks cost savings for individuals which can directly impact low-income populations' access to medicine.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency: The Secretary must make all records, documents, communications, and contracts available in a centralized, searchable, and downloadable format (Section 2(a)(1)).
-
Public Knowledge of Pricing Agreements: The bill requires the disclosure of agreements where manufacturers offer reduced prices based on prices paid in other nations (Section 2(a)(1)(A)).
-
Insight into Sales and Discounts: Information regarding manufacturer offerings of direct-to-consumer drug sales or discounts through specific platforms or partnerships must be released (Section 2(a)(1)(B)).
-
Economic Impact Awareness: The CBO and Comptroller General will publish a report detailing the expected economic and budgetary consequences of the disclosed agreements (Section 4).
-
Understanding Individual Savings: The required report will include an analysis of direct cost savings that individuals in the United States have received or can expect to receive, categorized by insurance status (Section 4(2)).
Potential Negative Impacts for People
-
Loss of Proprietary Information: The Secretary is permitted to withhold or redact certain information, such as proprietary pricing information or pricing protected by the laws of another nation (Section 2(c)).
-
Limited Information Access: The Secretary may withhold information that is part of a settlement agreement or a court directive (Section 2(c)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this lower the price of prescription medicines? — The bill targets the disclosure of agreements that involve reduced drug prices to increase transparency regarding costs. Does this strengthen the Affordable Care Act? — The bill requires a budget analysis of the impacts of agreements on qualified health plans offered through the ACA exchanges. Does this put more money into Medicaid, the health coverage for people on low incomes? — The bill mandates analysis of the impact of pricing agreements on the Medicaid program. Does this put more money into Medicare, the health coverage for people over 65? — The bill mandates analysis of the impact of pricing agreements on the Medicare program.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires the public release of documents, communications, and contracts related to drug pricing deals in a searchable format.
- Demographic And Interest Groups
- Would households on low incomes be better off under this? — The bill tracks cost savings for individuals which can directly impact low-income populations' access to medicine. Would middle-income households be better off under this? — Transparency in drug pricing may lead to more predictable costs for middle-income families. Would high-income households be better off under this? — The bill includes analysis of direct cost savings that individuals may receive.
- Economy And Finance
- Does this make the government pay for what it commits to? — The bill requires the CBO and GAO to analyze the economic and budgetary consequences of drug pricing agreements.
- National Security And Foreign Policy
- Does this increase the pay, pensions or support veterans receive? — Increased transparency in drug pricing may indirectly benefit those utilizing government-funded health benefits.
- Social Issues And Justice
- Is this likely to lift people out of poverty? — The bill tracks direct cost savings received by individuals which may assist low-income households.
- 7/16/2026
- 1 Cosponsor added.
- 7/15/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 23 Cosponsors added.
- Introduced in House
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Donald BeyerDemocrat · Virginia
Kathy CastorDemocrat · Florida
Yvette ClarkeDemocrat · New York
André CarsonDemocrat · Indiana
Lloyd DoggettDemocrat · Texas
Suzan DelBeneDemocrat · Washington
Maxine DexterDemocrat · Oregon
Dwight EvansDemocrat · Pennsylvania
Maggie GoodlanderDemocrat · New Hampshire
Summer LeeDemocrat · Pennsylvania
Kweisi MfumeDemocrat · Maryland
Betty McCollumDemocrat · Minnesota
Gwen MooreDemocrat · Wisconsin
Doris MatsuiDemocrat · California
Eleanor NortonDemocrat · District of Columbia
Jimmy PanettaDemocrat · California
Chris PappasDemocrat · New Hampshire
Deborah RossDemocrat · North Carolina
Janice SchakowskyDemocrat · Illinois
Bradley SchneiderDemocrat · Illinois
Paul TonkoDemocrat · New York
Mark TakanoDemocrat · California
Rashida TlaibDemocrat · Michigan
Nikema WilliamsDemocrat · Georgia